StreetAlpha
13F holdings · Q3 2026

Sanofi

Paris, I0 · files as Sanofi
Know the moment Sanofi filesYou follow Sanofi An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 5, 2026Next filing due Feb 15, 2027CIK 1121404

Sanofi reported 16 stocks worth $630M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are MGTX (21.3%), INBX (18.4%) and NVAX (11.8%). Compared with Q2 2026, the fund opened new positions in KRSA, ETRA and ATTO.

Latest filing: what Sanofi did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
6 new0 added0 trimmed0 sold outBought about $137M · sold about $0
New 6
See all 6 →
Added 0

None

Trimmed 0

None

Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$630M+17.9% vs last quarter
Stocks held166 new · 0 sold out
Top 5 weight68.7%very concentrated
Turnover22%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
MGTX
Meiragtx Hldgs PLC
$134M21.3%12.2MNo change8 of 8
2
INBX
Inhibrx Biosciences Inc
$116M18.4%1.2MNo change8 of 8
3
NVAX
Novavax Inc
$74.4M11.8%6.9MNo change8 of 8
4
KRSA
Korsana Biosciences Inc
$63.8M10.1%2MNew position1 of 8
5
ODTX
Odyssey Therapeutics, Inc.
$44.2M7.0%2MNo change2 of 8
6
ANAB
Anaptysbio Inc
$41.3M6.6%822KNo change8 of 8
7
AGMB
Agomab Therapeutics NV
$30.9M4.9%2.8MNo change3 of 8
8
TRAX
First Tracks Biotherapeutics
$29.1M4.6%822KNo change2 of 8
9
ETRA
Electra Therapeutics Inc
$27.7M4.4%2.5MNew position1 of 8
10
ATTO
Attovia Therapeutics Inc
$18.6M3.0%1.1MNew position1 of 8
🔒 6 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 8 quarters
$174MQ4 '24
$166MQ1 '25
$176MQ2 '25
$260MQ3 '25
$310MQ4 '25
$336MQ1 '26
$534MQ2 '26
$630MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 5, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Sanofi 13F FAQ

What does Sanofi own?

Sanofi reported 16 stocks worth $630M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are MGTX (21.3%), INBX (18.4%) and NVAX (11.8%). The table above lists every position in the filing (the top 10 without an account).

What did Sanofi buy and sell in Q3 2026?

Compared with Q2 2026: 6 new positions, 0 added to, 0 trimmed and 0 sold out. New positions include KRSA, ETRA and ATTO.

When will Sanofi file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Sanofi's portfolio worth?

The Q3 2026 filing reports $630M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.